3′,4′-Dihydroxyflavonol Inhibits Fibrotic Response in a Rabbit Model of Glaucoma Filtration Surgery
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910767 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Zoe Pasvanis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology, Department of Surgery, University of Melbourne, Fitzroy, VIC 3065, Australia. Hauptthemen laut MEDLINE: Glaucoma, Fibrosis, Flavonols, Filtering Surgery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Vision Research, University of Melbourne Annemarie Mankiewicz-Zelkin Fellowship.
Abstract (Originalsprache)
Post-operative fibrosis of the filtering bleb limits the success of glaucoma filtration surgery (GFS). To minimise subconjunctival scarring following GFS, treatment with antimetabolites such as Mitomycin C (MMC) has become standard practice; however, their use is associated with considerable side effects. This study aimed to investigate the anti-scarring properties of 3′,4′-dihydroxyflavonol (DiOHF). GFS was performed in New Zealand white rabbits who received eye drops of DiOHF three times daily and vehicle eye drops after surgery (n = 5) or a single intraoperative treatment of MMC (n = 5). Blebs were imaged immediately following surgery and on days 7, 15, 21, and 28 for clinical examination. On day 28, eyes were harvested to assess collagen deposition, expression of α-SMA, oxidative stress, angiogenesis, fibroblast activity, and inflammation in the conjunctiva/Tenon’s layer. At 7 and 28 days post-GFS, MMC-treated blebs were more ischaemic than DiOHF- or vehicle-treated blebs. On day 28, DiOHF treatment significantly suppressed collagen accumulation, CD31 expression, Vimentin expression, and CD45 expression compared to the vehicle control. No difference was observed in 3-Nitrotyrosine or αSMA expression between treatment groups. Treatment with DiOHF reduced conjunctival scarring and angiogenesis in rabbits with GFS, which was comparable to MMC. DiOHF may be a safer and more effective wound-modulating agent than conventional antifibrotic therapy in GFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ophthalmology, Department of Surgery, University of Melbourne, Fitzroy, VIC 3065, Australia.
- Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia.
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, VIC 3065, Australia.
- Glaucoma Research and Investigation Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia.
ORCID-Profile: Zoe Pasvanis, Elsa C Chan
Förderung
- Australian Vision Research
- University of Melbourne Annemarie Mankiewicz-Zelkin Fellowship
Zitieren
APA
Pasvanis, Z., Kong, R. C. K., Shah, M. H., Chan, E. C., & Fan Gaskin, J. C. (2024). 3′,4′-Dihydroxyflavonol Inhibits Fibrotic Response in a Rabbit Model of Glaucoma Filtration Surgery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910767
Vancouver
Pasvanis Z, Kong RCK, Shah MH, Chan EC, Fan Gaskin JC. 3′,4′-Dihydroxyflavonol Inhibits Fibrotic Response in a Rabbit Model of Glaucoma Filtration Surgery. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910767
BibTeX
@article{Pasvanis2024,
author = {Pasvanis, Zoe and Kong, Roy C K and Shah, Manisha H and Chan, Elsa C and Fan Gaskin, Jennifer C},
title = {3′,4′-Dihydroxyflavonol Inhibits Fibrotic Response in a Rabbit Model of Glaucoma Filtration Surgery},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910767}
}
EUVIMED